0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover462.13%IV-75.37%PremiumJan 17, 2025Expiry Date3.06Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9871Delta0.0105Gamma1.29Leverage Ratio-0.0050Theta0.0003Rho1.27Eff Leverage0.0002Vega
Biomea Fusion Stock Discussion
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study Thanks @Jaguar8 For spotting since for some reason they say no more posts???
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
No comment yet